Jan A Litwin Selected Research

Vx-11e

9/2020	Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells.
12/2019	Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan A Litwin Research Topics

Disease

6	Inflammation (Inflammations) 01/2020 - 06/2015
4	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2013
4	Chronic Renal Insufficiency 01/2020 - 01/2015
4	Leukemia 12/2019 - 01/2008
3	Neoplasms (Cancer) 07/2012 - 09/2010
2	Vascular Diseases (Vascular Disease) 01/2020 - 11/2019
2	Atherosclerosis 01/2020 - 01/2008
2	Vascular Calcification 01/2020 - 01/2013
2	Myeloid Leukemia (Leukemia, Myelocytic) 11/2018 - 01/2008
2	Atherosclerotic Plaque (Atheroma) 01/2018 - 01/2008
2	Dysplastic Nevus Syndrome (Dysplastic Nevus) 07/2012 - 09/2010
2	Melanoma (Melanoma, Malignant) 07/2012 - 09/2010
2	Nevus (Nevi) 07/2012 - 09/2010
1	Hematologic Neoplasms (Hematological Malignancy) 09/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2020
1	Kidney Diseases (Kidney Disease) 01/2018
1	Arteriovenous Fistula 01/2018
1	Aortic Valve Disease 01/2016
1	Hypertension (High Blood Pressure) 01/2013
1	Dyslipidemias (Dyslipidemia) 01/2013
1	Skin Neoplasms (Skin Cancer) 07/2012
1	Carcinogenesis 09/2010
1	Adenoma (Adenomas) 01/2007
1	Leiomyoma (Uterine Fibroids) 05/2003

Drug/Important Bio-Agent (IBA)

2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2020 - 11/2018
2	Vx-11eIBA 09/2020 - 12/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2015
2	MineralsIBA 01/2020 - 06/2015
2	vosaroxinIBA 12/2019 - 11/2018
2	CollagenIBA 11/2019 - 01/2007
2	Histone Deacetylase InhibitorsIBA 04/2014 - 07/2012
2	CyclinsIBA 07/2012 - 09/2010
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2020
1	Mitogen-Activated Protein KinasesIBA 09/2020
1	STA-21IBA 09/2020
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020
1	AntioxidantsIBA 01/2020
1	Proteoglycans (Proteoglycan)IBA 11/2019
1	GlycosaminoglycansIBA 11/2019
1	OsteopontinIBA 01/2019
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2019
1	TAK 733IBA 11/2018
1	Phosphates (Orthophosphate)IBA 01/2018
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2018
1	Fibroblast Growth Factor-23IBA 01/2018
1	ThrombomodulinIBA 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2017
1	PTX3 proteinIBA 01/2017
1	C-Reactive ProteinIBA 01/2017
1	LigandsIBA 01/2016
1	OsteoprotegerinIBA 01/2016
1	Advanced Glycation End ProductsIBA 01/2015
1	N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA 04/2014
1	Vorinostat FDA Link 04/2014
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2014
1	Glucose (Dextrose)FDA LinkGeneric 01/2013
1	Cyclin AIBA 07/2012
1	Etoposide (VP 16)FDA LinkGeneric 07/2012
1	theasinensin AIBA 07/2012
1	trichostatin A (A 300)IBA 07/2012
1	Valproic Acid (Depakote)FDA LinkGeneric 07/2012
1	Cyclin D3IBA 09/2010
1	Proteins (Proteins, Gene)FDA Link 09/2010
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2010
1	Cyclin D1IBA 09/2010
1	Apolipoproteins E (ApoE)IBA 01/2008
1	LDL Receptors (LDL Receptor)IBA 01/2008
1	phorbolIBA 01/2008
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2008
1	ApolipoproteinsIBA 01/2008
1	Pharmaceutical PreparationsIBA 01/2008
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2007
1	Hematoxylin (Haematoxylon)IBA 01/2007
1	Capsules (Microcapsules)IBA 05/2003
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2003

Therapy/Procedure

2	Renal Dialysis (Hemodialysis) 01/2020 - 01/2018